<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03790423</url>
  </required_header>
  <id_info>
    <org_study_id>AK2018_1</org_study_id>
    <secondary_id>2015-005583-42</secondary_id>
    <nct_id>NCT03790423</nct_id>
  </id_info>
  <brief_title>18F-ASIS PET/CT Imaging of Tissue Factor Expression In Patients With Primary and Metastastic Cancer</brief_title>
  <official_title>Phase I: PET Imaging of Tissue Factor (TF) Expression in Patients With Primary and Metastastic Cancer Using 18F-ASIS.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the trial is to test the new radio tracer 18F-ASIS for PET imaging&#xD;
      of tissue factor (TF) expression. The tracer has the potential of identifying tumors with&#xD;
      high levels of TF expression, which is expected to correlate with tumor aggression and&#xD;
      prognosis. Furthermore, the tracer can potentially be used as companion imaging diagnostic&#xD;
      agent for identifying patients eligible for TF directed therapies.&#xD;
&#xD;
      This is a first-in-man study to test the radio tracer in cancer patients. Safety,&#xD;
      biodistribution and dosimetry will be evaluated by repeated PET imaging (1 hour, 2 hours and&#xD;
      4 hours post-injection).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the trial is to test the new radio tracer 18F-ASIS for PET imaging&#xD;
      of tissue factor (TF) expression. The tracer has the potential of identifying tumors with&#xD;
      high levels of TF expression, which is expected to correlate with tumor aggression and&#xD;
      prognosis. Furthermore, the tracer can potentially be used as companion imaging diagnostic&#xD;
      agent for identifying patients eligible for TF directed therapies.&#xD;
&#xD;
      This is a first-in-man study to test the radio tracer in cancer patients. Safety,&#xD;
      biodistribution and dosimetry will be evaluated by repeated PET imaging (1 hour, 2 hours and&#xD;
      4 hours post-injection).&#xD;
&#xD;
      The primary end points are safety, biodistribution and dosimetry of 18F-ASIS. In addition,&#xD;
      the quantitative uptake of 18F-ASIS will be compared to the expression of TF measured&#xD;
      directly in tumor tissue obtained by surgery or biopsies. The study will be monitored and&#xD;
      evaluated in accordance with the principles of Good Clinical Practice (GCP).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 3, 2019</start_date>
  <completion_date type="Actual">November 18, 2019</completion_date>
  <primary_completion_date type="Actual">November 18, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1.Biodistribution of the radiotracer 18F-ASIS estimated by PET</measure>
    <time_frame>4 hours</time_frame>
    <description>The biodistribution of the 18F-ASIS radiotracer estimated from the standardized uptake values (SUV) of the major organs obtained from the patient's repeated PET imaging with the radiotracer 18F-ASIS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>2.Dosimetry of the radiotracer 18F-ASIS estimated by PET</measure>
    <time_frame>4 hours</time_frame>
    <description>Dosimetry will be calculated with the use of OLINDA/EXM software (mSv) based on repeated PET imaging with the radiotracer 18F-ASIS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>3. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>48 hours</time_frame>
    <description>The safety of 18F-ASIS PET as measured by the number of participants with adverse events within 48 hours following the 18F-ASIS PET assessed by CTCAE v5.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1.Quantitative uptake of the radiotracer 18F-ASIS in tumor tissue</measure>
    <time_frame>4 hours</time_frame>
    <description>The patients will be PET scanned 1 hour, 2 hours and 4 hours post-injection of the radiotracer 18F-ASIS. These timepoints will be used for assessment of tumor uptake by the use of maximum and mean standardized uptake value (SUV).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Cervix Cancer</condition>
  <arm_group>
    <arm_group_label>18F-ASIS PET</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One injection of 18F-ASIS (app. 200 MBq) followed by 3 PET/CT scans 1 hour, 2 hours and 4hours post-injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Injection of 18F-ASIS</intervention_name>
    <description>Each patient will receive one injection of 18F-ASIS (approximately 200 Mbq)</description>
    <arm_group_label>18F-ASIS PET</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PET/CT scan</intervention_name>
    <description>Following one injection of 18F-ASIS the patients will be PET/CT scanned at 1 hour, 2 hours and 4 hours post-injection</description>
    <arm_group_label>18F-ASIS PET</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with breast, lung, pancreatic, cervix or ovarian cancer&#xD;
&#xD;
          -  Capable of understanding the patient information in Danish and giving full informed&#xD;
             consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Breast-feeding&#xD;
&#xD;
          -  Weight above 140 kg&#xD;
&#xD;
          -  History of allergic reaction attributable to compounds of similar chemical or biologic&#xD;
             composition to 18F-ASIS&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mathias D Loft, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>December 20, 2018</study_first_submitted>
  <study_first_submitted_qc>December 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 31, 2018</study_first_posted>
  <last_update_submitted>November 17, 2020</last_update_submitted>
  <last_update_submitted_qc>November 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Mathias Dyrberg Loft</investigator_full_name>
    <investigator_title>Principal Investigator, MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

